Here are the 10-K annual reports from Anteris Technologies Global Corp. (AVR) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow AVR and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full AVR filings page.
Anteris Technologies Global Corp. files its annual report describing a development-stage structural heart company focused on the DurAVR® transcatheter heart valve (THV) system for aortic stenosis. DurAVR® combines a single-piece biomimetic valve made from proprietary ADAPT® anti-calcification tissue with the ComASUR® balloon-expandable delivery system.
More than 130 patients have received DurAVR® worldwide through first-in-human, early feasibility and compassionate-use cases, showing favorable hemodynamics and high technical success in small aortic annuli. In 2025, Anteris began a global randomized pivotal Trial comparing DurAVR® to approved TAVR devices, enrolling first patients in Denmark after European approval and securing a staged FDA IDE for the first 200 U.S. patients.
The company targets a growing TAVR market that FMI estimates could reach $9.9 billion for severe aortic stenosis and $2.5 billion for valve-in-valve procedures by 2028, with North America and Europe as core regions. Anteris remains loss-making, relies on single-source suppliers and development partners, holds 47 active patents and 75 pending applications as of December 31, 2025, and faces extensive clinical, regulatory, financing and competitive risks highlighted in its risk factor summary.